J&J profit boosted by better-than-expected pharma unit sales
Johnson & Johnson beat quarterly profit estimates on higher sales at its pharmaceuticals unit even as it faces fierce competition for some of its biggest drugs, sending the company’s shares up more than 2 percent.
